# Endoscopic ultrasound-guided radiofrequency ablation for treatment of pancreatic neuroendocrine tumors: Multicenter prospective study

## TL;DR

A study shows that endoscopic ultrasound-guided radiofrequency ablation is a safe and effective treatment for both functional and non-functional pancreatic neuroendocrine tumors.

## Contribution

This is the first large prospective multicenter study evaluating the safety and effectiveness of EUS-RFA for pancreatic neuroendocrine tumors.

## Key findings

- EUS-RFA achieved 96.7% symptom resolution in patients with insulinomas.
- EUS-RFA achieved 88% complete radiological response in non-functional pancreatic neuroendocrine tumors.
- Adverse events occurred in 15% of patients, with only one severe event.

## Abstract

Endoscopic ultrasound-guided radiofrequency ablation (EUS-RFA) has been proposed as a minimally invasive alternative to surgery for treatment of both functional (F-) and non-functional (NF-) pancreatic neuroendocrine tumors (PanNETs). We performed a large prospective multicenter study to evaluate safety and effectiveness of EUS-RFA in patients with F- and NF-PanNETs.

Patients with F- (≤ 2 cm) and NF-PanNETs (15 mm-25 mm) were prospectively enrolled over a 43-month period. The primary aim was safety, defined as rate of adverse events (AEs). The secondary aim was effectiveness defined as complete disappearance of the hormonal secretion syndrome in F- PanNETs, whereas for NF-PanNETs, complete response was defined as absence of enhancing tissue and of detectable lesion at magnetic resonance imaging/computed tomography scan and Gallium-positron emission tomography, respectively. The EUSRA 19G needle was used in all patients. After treatment completion, follow-up was performed for 1 year.

During the study period, a total of 60 patients were enrolled, 30 with insulinomas and 30 with NF-PanNETs (mean lesion size 14.5 ± 4.5 mm). In 78.3% of patients, a single RFA session was performed. Overall, AEs occurred in nine of 60 patients (15%), in four patients (13.3%) with insulinomas and in five (16.7%) with NF-PanNETs, with only one severe AE. Complete insulin hypersecretion symptom resolution was obtained in 29 of 30 patients (96.7%) with insulinomas, whereas for NF-PanNETs, complete radiological response was obtained in 22 of 25 patients (88%) with long-term follow up.

Our prospective international multicenter study demonstrated that EUS-RFA is highly safe and effective for the treatment for both F- and NF-PanNETs.